Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...
Syfovre was approved for the treatment of geographic ... Apellis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency confirmed its June ...
Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...
a large Medicare Advantage plan will make SYFOVRE the only preferred product on its formulary. Received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback